Abiopharma

New Form 8-K - Amphastar Pharmaceuticals, Inc. Filed: 2025-08-12 AccNo: 0001558370-25-011134 Size: 195 KB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

New Form 4 - electroCore, Inc. Filed: 2025-08-12 AccNo: 0001641172-25-023084 Size: 6 KB

New Form SCHEDULE 13G/A - Zai Lab Ltd Filed: 2025-08-12 AccNo: 0000950103-25-010166 Size: 15 KB

New Form 6-K - GSK plc Filed: 2025-08-12 AccNo: 0001654954-25-009371 Size: 5 MB

New Form SCHEDULE 13G/A - ICON PLC Filed: 2025-08-12 AccNo: 0001193125-25-178416 Size: 144 KB

New Form SCHEDULE 13G - Stevanato Group S.p.A. Filed: 2025-08-12 AccNo: 0000950170-25-106893 Size: 141 KB

New Form SCHEDULE 13G - Privia Health Group, Inc. Filed: 2025-08-12 AccNo: 0000950103-25-010165 Size: 20 KB

New Form SCHEDULE 13G - RxSight, Inc. Filed: 2025-08-12 AccNo: 0001193125-25-178415 Size: 141 KB

New Form SCHEDULE 13G/A - VERACYTE, INC. Filed: 2025-08-12 AccNo: 0001193125-25-178383 Size: 141 KB

New Form EFFECT - Envoy Medical, Inc. Filed: 2025-08-11 AccNo: 9999999995-25-002550 Size: 1 KB

Haw Par Corporation Limited - Announcement

Amphastar Pharmaceuticals Bolsters Proprietary Pipeline Through Exclusive Licensing Agreement with Nanjing Anji Biotechnology Co., Ltd.

Other Scheme of Arrangement: LEAVE TO CONVENE THE SCHEME MEETING IN RELATION TO THE SCHEME

General Announcement: CHANGES IN SUBSTANTIAL SHAREHOLDERS INTEREST PURSUANT TO SECTION 138 OF THE COMPANIES ACT 2016

KEYTRUDA® (pembrolizumab) plusPadcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free and Overall Survival and Pathologic Complete Response Rate for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery